Deal Team

Corporate
Antitrust
Executive Compensation and Benefits
Finance
Intellectual Property
Litigation
Tax

Abbott in its $22 billion acquisition of Exact Sciences

On November 20, 2025, Abbott Laboratories (NYSE: ABT) and Exact Sciences Corporation (NASDAQ: EXAS) announced an agreement for Abbott to acquire Exact Sciences for $105 per share in cash, representing an enterprise value of $22 billion.  Exact Sciences is a leading provider of cancer screening and diagnostic solutions, including the Cologuard and Oncotype DX tests, and the transaction represents the largest medical technology M&A transaction of the year.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Abbott.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.